TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02877979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS003 vaginal tablet
Description: The trial will be conducted in three cohorts of 12 women each. In each cohort, participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17. In each cohort, therefore, 9 participants will receive DS003 vaginal tablets and 3 participants will receive placebo vaginal tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04361188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MAC anesthesia
Description: Patients receives DBS under monitored anesthesia care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AAA anesthesia
Description: Patients receives DBS under asleep-awake-asleep anesthesia.
Study: NCT00240045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine, albumin, octreotide LAR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midodrine, octreotide, albumin
Description: midodrine up to 12.5 mg tid, octreotide LAR 20 mg im once, albumin 150 mg q weekly
Study: NCT03371498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone placebo
Description: Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
Study: NCT00813241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib reference formulation
Description: 200 mg single oral dose of celecoxib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib test formulation A1
Description: 150 mg single oral dose of celecoxib A1 formulation tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib test formulation B2
Description: 150 mg single oral dose of celecoxib B2 formulation tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib test formulation C1
Description: 150 mg single oral dose of celecoxib Cl formulation tablets
Study: NCT00408317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrase® MT20
Description: Ultrase® MT 20 capsules containing enteric-coated minitablets orally daily at a dose stabilized during the first stabilization period (4 days), as per investigator's discretion, for 6 to 7 days in either first intervention period or second intervention period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to Ultrase® MT 20 capsules orally daily for 6 to 7 days in either first intervention period or second intervention period.
Study: NCT01238068

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gamma nail stryker
Description: for acute unstable pertrochantric fractures the subjects will be treated randomaly with either Gamma nail device Vs Dynamic hip screw
Study: NCT02317900

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TV005
Description: TV005 is a live attenuated recombinant tetravalent dengue virus vaccine. It will be administered as a 0.5 mL dose containing 10\^3 plaque forming units (PFUs) of each component (10\^3.3 PFUs/mL of rDEN1∆30, 10\^4.3 PFU/mL of rDEN2/4∆30(ME), 10\^3.3 PFU/mL of rDEN3∆30/31-7164 and 10\^3.3 PFU/mL of rDEN4∆30). It will be delivered by subcutaneous injection in the deltoid region of the upper arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo vaccine will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rDEN2∆30-7169
Description: rDEN2∆30-7169 is a live recombinant attenuated DENV-2 candidate vaccine virus. It will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2∆30-7169
Description: rDEN2∆30-7169 is a live recombinant attenuated DENV-2 candidate vaccine virus. It will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
Study: NCT05972980

Intervention type: OTHER
Intervention: COVID-19
Description: The investigators stratified our population based on COVID-19 virus positivity to identify any risk factors in this population compared to the NON-COVID-19 population.
Study: NCT02396199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents
Description: Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
Study: NCT01213316

Intervention type: DRUG
Intervention: Raltegravir
Description: Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 48 or 144 weeks

Intervention type: DRUG
Intervention: Raltegravir
Description: Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 96, 144, or 48 weeks
Study: NCT02190695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: 20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: 0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.
Study: NCT01774721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib (PF-00299804)
Description: Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Gefitinib 250 mg tablets, continuous oral daily dosing.
Study: NCT04016935

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT00842335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JI-101
Description: JI-101, 50 mg capsules, will be administered daily for up to 112 days (four 28-day cycles); treatment may be extended if, in the opinion of the investigator, a patient has tolerated the treatment and appears to be benefitting from receiving study medication
Study: NCT04336774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caption AI
Description: Software program that guides the investigator or any other non-sonographer to take the best possible pictures of the heart.
Study: NCT00959855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Sixteen, two hourly pulmonary rehabilitation sessions over an eight week period. The first hour will consist of an individualized exercise programme based on exercise field tests. The second hour will consist of an educational component. A home exercise programme of inspiratory muscle training (Threshold(R)IMT (respiratory muscle trainer re:HS730EU-001 single patient use) starting between 15% -30% of PiMax and progress weekly to 60% for 30 mins a day/ 5 dats a week with an inspiratory/expiratory ratio of 3:4. Patients will also be encouraged to walk or undertake an home exercise programme based on a Borg score of between 3 and 5 an additional 3 days a week.
Study: NCT02732574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscilatory Positive Expiratory Pressure (OPEP) device
Description: OPEP devices will be set to the highest pressure setting tolerated on POD #1. If the highest pressure setting is not achieved on POD#1, the PT will increase the pressure daily with the aim to achieve the highest pressure setting as soon as tolerated by the patient or POD#3, whichever comes first. Patients will be instructed to complete 15 breaths in a seated position with the OPEP device twice per waking hour. This will occur in addition to usual care.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM Device Group
Description: SHAM devices will be provided to patients on POD #1 and set to the highest pressure setting externally, however no positive expiratory pressure will be provided as the internal pressure regulating mechanism has been removed. Patients will be instructed to complete 15 breaths in a seated position with the sham device twice per waking hour. This will occur in addition to usual care.
Study: NCT03694353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvaliase
Description: 40-60mg/day
Study: NCT03806361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafts supplemented with ADRC
Description: Isolation of ADRC from fat aspirates and its use for supplementation of fat grafts.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Structural fat grafting
Description: Fat grafts without supplementation of ADRC
Study: NCT03501849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polypectomy using a cold snare
Description: Polypectomy by cold-snare technique
Study: NCT03633032

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Acquiring of ultrashort echo time (UTE) MRI sequences
Description: Modern MRI sequences (ultrashort echo time (UTE)) for a better depiction of bone anatomy
Study: NCT02682524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pelubiprofen CR 45mg tab.
Study: NCT02802826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Exercise Prescription
Description: The intervention is a walking- based exercise prescription with the aim of a graduated increase in exercise to achieve national guidelines (i.e. Over 150mins of moderate intensity exercise over a week).
Study: NCT02679131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.
Study: NCT00760006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unasyn
Description: Subjects will receive the antibiotic or the saline placebo 30 minutes prior to the initial incision in their palatoplasty procedure. The FDA approved antibiotic used for this study is Unasyn. Unasyn is a first-line measure, used by ENT surgeons at Children's Hospital of Pittsburgh for antibiotic treatment of virtually all ear, nose and throat infections. The use of Unasyn for this study is off-label as with the majority of antibiotics used with children. Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm.
Study: NCT00655291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP20B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00640081

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT00180323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renewal
Description: Renewal is a CRT-D device for cardiac resynchronization therapy
Study: NCT00665158

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UC (Usual Care Group)
Description: Usual Care Group - Treatment Implementation by Primary Care Physician

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BI (Behavioral Intervention Group)
Description: Behavioral Intervention Group - Treatment Implementation by Health Educator
Study: NCT01795664

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Functional Respiratory Imaging
Description: CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Functional Respiratory Imaging
Description: CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate and Fluticasone propionate HFA pMDI
Description: Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Evohaler
Description: Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Test product
Description: Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Reference product
Description: Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day.
Study: NCT02336750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: 125mg D1, 80mg D2-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: 125mg D1, 80mg D2-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: 15mg D2-4
Study: NCT04446533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide and Hyaluronic acid filming formulation
Description: Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of BMG0703 will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine 0.2%
Description: Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with Chlorhexidine 0.2% by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of Chlorhexidine 0.2% will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with a placebo product by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of the placebo product will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth).
Study: NCT03558594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Behavioral Condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Behavioral Condition
Study: NCT01803568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 weeks of exercise; 4 times pr week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 weeks of exercise; 4 times pr week
Study: NCT01195285

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-Incision Laparoscopic Surgery cholecystectomy
Description: Laparoscopic Cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Laparoscopic Cholecystectomy (TLC)
Description: Laparoscopic Cholecystectomy
Study: NCT01590017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Study: NCT03363763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus 0.2%
Description: Ointment for topical administration hs x 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus 0.4%
Description: Ointment for topical administration hs x 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Placebo ointment comparator for topical administration hs x 12 weeks
Study: NCT00657670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ready-made spectacles
Description: Ready-made spectacles will be dispensed to correct refractive error. Ready-made spectacles are spectacles which are available from an existing inventory. This is different to prescription spectacles which are usually made to order. They have the same spherical power for the right and left eyes and do not include a correction for astigmatism. The limited inventory for this trial includes +1.00 to +4.00 in 0.50 steps, +5.00, +6.00 and +8.00, -1.00 to -6.00 in 0.50 steps, -7.00, -8.00, -9.00 and -10.00. The appropriate spectacles are selected based on the spherical equivalent refractive error. If there is a difference between the two eyes the lower correction is selected.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Spectacles will be prescribed to correct refractive error. These spectacles will be custom-prescribed based on the sphero-cylindrical refractive correction. The spectacles used in this arm will be custom made for each participant based on their refraction and can be made in a full range of spherical powers and astigmatic corrections for up to 2.00 dioptres of cylinder.
Study: NCT03616197

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: free gingival graft
Description: A horizontal incision was made along the mucogingival line with a scalpel number 15 to prepare a bed of periosteum and a thin immobilized connective tissue. The moving gingival tissues were removed coronally, and the bed was prepared so that the immobilized keratinized gingival tissue was preserved and the graft was placed apically. The template of the recipient region was placed in the donor region to be 2-3 mm more apically than the gingival margins of the teeth. The number of 15 scalpel was used to make incision at the template border and perpendicular to the keratinized tissue. The graft thickness was standardized in all patients between 1.5-2 mm. FGG was placed over the recipient bed and 5/0 non-resorbable monofilament sutures were used for fixing the four corners of the graft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: free gingival graft
Description: A horizontal incision was made along the mucogingival line with a scalpel number 15 to prepare a bed of periosteum and a thin immobilized connective tissue. The moving gingival tissues were removed coronally, and the bed was prepared so that the immobilized keratinized gingival tissue was preserved and the graft was placed apically. The template of the recipient region was placed in the donor region to be 2-3 mm more apically than the gingival margins of the teeth. The number of 15 scalpel was used to make incision at the template border and perpendicular to the keratinized tissue. The graft thickness was standardized in all patients between 1.5-2 mm. FGG was placed over the recipient bed and 5/0 non-resorbable monofilament sutures were used for fixing the four corners of the graft.
Study: NCT00871780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00002 (natalizumab)
Study: NCT00875654

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume\<100ml) less than 6 weeks after stroke

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume\<100ml) less than 6 weeks after stroke